Back to search results

Improving Blood Clot Prevention After Cancer Surgery

This study aims to improve how often patients receive medication to prevent blood clots (venous thromboembolism or VTE) after major cancer surgery. Blood clots like deep vein thrombosis (DVT) and pulmonary embolism (PE) can be serious, but preventative medications are often not used after patients leave the hospital. This study will provide surgeons with education and an electronic medical record tool to help them prescribe these important medications more consistently. We want to see if these tools help more eligible patients receive and take their blood clot prevention medicine for 30 days after surgery. This study is for surgeons within the Medical University of South Carolina (MUSC) system who perform specific cancer surgeries.

Study design
This interventional study plans to enroll 30 participants. It uses a "surgeon cluster" design, meaning the intervention focuses on groups of surgeons.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure how many patients receive preventative medication throughout the 30-month study duration. Patient adherence to medication will be checked 30 days after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06451003

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

Recruiting
NAAges 18+InterventionalTreatment
Medical University of South Carolina
~30 participants
Updated 2025-07-31 on ClinicalTrials.gov
What's tested:Exposure to clinical decision support system and education

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of eligible patients receiving venous thromboembolism (VTE) prophylaxis prescription; surgeon cluster level analysis
Measured over Study duration: 30 months including pre-intervention (range: 6-18 months) and post-intervention (range: 9-21 months)
+1 more outcome measured

Conditions

Venous Thromboembolism
Pulmonary Embolism
Deep Vein Thrombosis
Cancer
Surgery

Explore related trials

Malignant NeoplasmVenous Thromboembolism

Where it's being run

1 sites across 1 states
South Carolina1

Study leadership

  • Thomas Curran, MD MPH · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina

Who to contact

Thomas Curran, MD MPH
[email protected]
843-876-4846
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

We will exclude patients receiving preoperative therapeutic anticoagulation within 30 days preoperatively, patients initiating therapeutic anticoagulation postoperatively and patients with chronic kidney disease grade 3 or higher. Patients with postoperative length of stay 30 days or greater will be excluded as ePpx duration is for 30 days postoperative.
We will exclude patients receiving preoperative therapeutic anticoagulation within 30 days preoperatively, patients initiating therapeutic anticoagulation postoperatively and patients with chronic kidney disease grade 3 or higher. Patients with postoperative length of stay 30 days or greater will be excluded as extended pharmacologic venous thromboembolism duration is for 30 days postoperative.
Lack of survey response.

What this trial measures

  • Proportion of eligible patients receiving venous thromboembolism (VTE) prophylaxis prescription; surgeon cluster level analysisStudy duration: 30 months including pre-intervention (range: 6-18 months) and post-intervention (range: 9-21 months)

    Proportion of eligible patients receiving prescription for guideline concordant post-discharge VTE prophylaxis.

  • Proportion of patients adherent to pharmacologic extended venous thromboembolism prophylaxis (ePpx)30 days postoperative

    Patient reported via REDCap survey. Adherence will be defined as the percentage of days covered with treatment during the prescription period (i.e. duration at discharge) which has been used previously to assess ePpx. This will include filled prescription and approximate number of doses administered out of number of doses prescribed. Patients without access to electronic mail will be contacted by telephone.